Effects of exposure to 12C and 4He particles on cognitive performance of intact and ovariectomized female rats

Autor: Barbara Shukitt-Hale, Bernard M. Rabin, Christina Spadafora, Alison Larsen, Lorraine A. Dell'Acqua, Marshall G. Miller, Nicholas N. Zolnerowich

Publikováno v: Life Sciences in Space Research. 22:47-54

Exposure to the types of radiation encountered outside the magnetic field of the earth can disrupt cognitive performance. Exploratory class missions to other planets will include both male and female astronauts. Because estrogen can function as a neu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::70199b4cbc1157f63ca92d7a8c8d1190
https://doi.org/10.1016/j.lssr.2019.07.005

Active DNA demethylation promotes cell fate specification and the DNA damage response.

Autor: Wang D; Laboratory of Genome Integrity, National Cancer Institute NIH, Bethesda, MD, USA., Wu W; Laboratory of Genome Integrity, National Cancer Institute NIH, Bethesda, MD, USA.; State Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China., Callen E; Laboratory of Genome Integrity, National Cancer Institute NIH, Bethesda, MD, USA., Pavani R; Laboratory of Genome Integrity, National Cancer Institute NIH, Bethesda, MD, USA., Zolnerowich N; Laboratory of Genome Integrity, National Cancer Institute NIH, Bethesda, MD, USA., Kodali S; Stem Cells and Regenerative Medicine, Center for Cell and Gene Therapy, Department of Molecular and Cellular Biology and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.; Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zong D; Laboratory of Genome Integrity, National Cancer Institute NIH, Bethesda, MD, USA., Wong N; Laboratory of Genome Integrity, National Cancer Institute NIH, Bethesda, MD, USA., Noriega S; Laboratory of Genome Integrity, National Cancer Institute NIH, Bethesda, MD, USA., Nathan WJ; Laboratory of Genome Integrity, National Cancer Institute NIH, Bethesda, MD, USA., Matos-Rodrigues G; Laboratory of Genome Integrity, National Cancer Institute NIH, Bethesda, MD, USA., Chari R; Genome Modification Core, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Kruhlak MJ; Laboratory of Cancer Biology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA., Livak F; Laboratory of Genome Integrity, National Cancer Institute NIH, Bethesda, MD, USA., Ward M; National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA., Caldecott K; Genome Damage and Stability Centre, University of Sussex, Falmer Brighton, UK., Di Stefano B; Stem Cells and Regenerative Medicine, Center for Cell and Gene Therapy, Department of Molecular and Cellular Biology and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.; Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nussenzweig A; Laboratory of Genome Integrity, National Cancer Institute NIH, Bethesda, MD, USA.

Publikováno v: Science (New York, N.Y.) [Science] 2022 Dec 02; Vol. 378 (6623), pp. 983-989. Date of Electronic Publication: 2022 Dec 01.

Role of 53BP1 in end protection and DNA synthesis at DNA breaks.

Autor: Paiano J; Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA., Zolnerowich N; Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA., Wu W; Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA., Pavani R; Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA., Wang C; Department of Cancer Genetics and Epigenetics, Beckman Research Institute of City of Hope, Duarte, California 91010, USA., Li H; Department of Cancer Genetics and Epigenetics, Beckman Research Institute of City of Hope, Duarte, California 91010, USA.; Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, California 91010, USA., Zheng L; Department of Cancer Genetics and Epigenetics, Beckman Research Institute of City of Hope, Duarte, California 91010, USA.; Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, California 91010, USA., Shen B; Department of Cancer Genetics and Epigenetics, Beckman Research Institute of City of Hope, Duarte, California 91010, USA.; Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, California 91010, USA., Sleckman BP; Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA., Chen BR; Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA., Nussenzweig A; Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

Publikováno v: Genes & development [Genes Dev] 2021 Oct 01; Vol. 35 (19-20), pp. 1356-1367. Date of Electronic Publication: 2021 Sep 09.

CTCF is a barrier for 2C-like reprogramming.

Autor: Olbrich T; Laboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA., Vega-Sendino M; Laboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA., Tillo D; Genetics Branch, CCR, NCI, NIH, Bethesda, MD, USA., Wu W; Laboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA., Zolnerowich N; Laboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA., Pavani R; Laboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA., Tran AD; Laboratory of Cancer Biology and Genetics, CCR, NCI, NIH, Bethesda, MD, USA., Domingo CN; Laboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA., Franco M; Laboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA., Markiewicz-Potoczny M; Laboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA., Pegoraro G; Laboratory of Receptor Biology and Gene Expression, CCR, NCI, NIH, Bethesda, MD, USA., FitzGerald PC; Genome Analysis Unit, CCR, NCI, NIH, Bethesda, MD, USA., Kruhlak MJ; Laboratory of Cancer Biology and Genetics, CCR, NCI, NIH, Bethesda, MD, USA., Lazzerini-Denchi E; Laboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA., Nora EP; Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA.; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA., Nussenzweig A; Laboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA., Ruiz S; Laboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA. sergio.ruizmacias@nih.gov.

Publikováno v: Nature communications [Nat Commun] 2021 Aug 11; Vol. 12 (1), pp. 4856. Date of Electronic Publication: 2021 Aug 11.